BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 49 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $198 | 0.0% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $198 | -3.9% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $206 | +3.5% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $199 | -99.9% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $199,000 | +0.5% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $198,000 | -99.5% | 200,000 | -50.0% | 0.00% | -99.3% |
| Q1 2022 | $40,316,000 | +91.4% | 400,000 | +100.0% | 0.15% | +125.8% |
| Q4 2021 | $21,062,000 | +20348.5% | 200,000 | +100.0% | 0.07% | – |
| Q3 2021 | $103,000 | -50.5% | 100,000 | -50.0% | 0.00% | – |
| Q2 2021 | $208,000 | -49.3% | 200,000 | -50.0% | 0.00% | -100.0% |
| Q1 2021 | $410,000 | -4.7% | 400,000 | 0.0% | 0.00% | – |
| Q4 2020 | $430,000 | +105.7% | 400,000 | +100.0% | 0.00% | -100.0% |
| Q3 2020 | $209,000 | -57.5% | 200,000 | -50.0% | 0.00% | -50.0% |
| Q2 2020 | $492,000 | +16.0% | 400,000 | 0.0% | 0.00% | -33.3% |
| Q4 2019 | $424,000 | – | 400,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |